MICHAEL KORENFELD
- Type
- Physician · Allopathic & Osteopathic Physicians / Ophthalmology
- Where
- WASHINGTON, MO
- NPI
- 1174515613
- Received
- $63,517 in 47 records, 2019 to 2025 ($37,207 general, $26,310 research)
- As principal investigator
- $784,131 of research payments to others in 56 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 3 | $207 |
| 2024 | General payment | 11 | $462 |
| 2023 | General payment | 6 | $233 |
| 2022 | General payment | 5 | $1,294 |
| 2021 | General payment | 3 | $18,817 |
| 2020 | General payment | 3 | $8,487 |
| 2019 | General payment | 14 | $7,703 |
| 2019 | Research payment | 2 | $26,310 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Bausch Health US, LLC | 4 | $27,817 | 2019–2020 |
| EyePoint Pharmaceuticals US, Inc. | 6 | $27,379 | 2019–2022 |
| Osmotica Pharmaceutical Corp. | 4 | $5,883 | 2019 |
| Novartis Pharmaceuticals Corporation | 7 | $1,357 | 2019–2022 |
| Tarsus Pharmaceuticals, Inc. | 2 | $281 | 2024–2025 |
| Thea Pharma Inc. | 7 | $231 | 2023–2025 |
| NEW WORLD MEDICAL,INC. | 5 | $184 | 2022–2024 |
| Johnson & Johnson Health Care Systems Inc. | 1 | $113 | 2023 |
| Allergan, Inc. | 1 | $81 | 2019 |
| Alcon Vision LLC | 3 | $56 | 2022–2024 |
| Glaukos Corporation | 3 | $48 | 2024 |
| ABBVIE INC. | 1 | $26 | 2025 |
| Bausch & Lomb Americas Inc. | 1 | $21 | 2024 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $17 | 2019 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 7 | $35,015 |
| Research payment | 2 | $26,310 |
| Food and Beverage | 34 | $1,898 |
| Travel and Lodging | 3 | $180 |
| Debt forgiveness | 1 | $113 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-10-19 | Thea Pharma Inc. | $31 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2025 | |
| 2025-10-18 | Tarsus Pharmaceuticals, Inc. | $150 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-03-27 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | LUMIGAN Drug, EYE CARE | 2025 | |
| 2024-10-24 | Thea Pharma Inc. | $23 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2024 | |
| 2024-10-19 | Tarsus Pharmaceuticals, Inc. | $131 | Food and Beverage | In-kind items and services | XDEMVY Drug, DEMODEX BLEPHARITIS | 2024 | |
| 2024-10-19 | Thea Pharma Inc. | $36 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2024 | |
| 2024-08-08 | Glaukos Corporation | $13 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-05-05 | Thea Pharma Inc. | $46 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2024 | |
| 2024-04-30 | Glaukos Corporation | $20 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-04-06 | NEW WORLD MEDICAL,INC. | $109 | Food and Beverage | In-kind items and services | Kahook Dual Blade Device, Ophthalmology | 2024 | |
| 2024-04-06 | Thea Pharma Inc. | $27 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2024 | |
| 2024-03-19 | Glaukos Corporation | $15 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-02-22 | Bausch & Lomb Americas Inc. | $21 | Food and Beverage | In-kind items and services | VYZULTA Drug, Ophthalmology | 2024 | |
| 2024-01-31 | Alcon Vision LLC | $15 | Food and Beverage | In-kind items and services | Centurion Device, Ophthalmology | 2024 | |
| 2023-11-29 | Alcon Vision LLC | $21 | Food and Beverage | In-kind items and services | Centurion Device, Ophthalmology | 2023 | |
| 2023-11-05 | Thea Pharma Inc. | $50 | Food and Beverage | In-kind items and services | IYUZEH Drug, OPHTHALMOLOGY | 2023 | |
| 2023-11-03 | Johnson & Johnson Health Care Systems Inc. | $113 | Debt forgiveness | In-kind items and services | 2023 | ||
| 2023-08-09 | NEW WORLD MEDICAL,INC. | $14 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-08 | Thea Pharma Inc. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-04-26 | NEW WORLD MEDICAL,INC. | $18 | Food and Beverage | In-kind items and services | 2023 | ||
| 2022-12-07 | NEW WORLD MEDICAL,INC. | $18 | Food and Beverage | In-kind items and services | Kahook Dual Blade Device, Ophthalmology | 2022 | |
| 2022-11-23 | EyePoint Pharmaceuticals US, Inc. | $326 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2022 | |
| 2022-06-07 | NEW WORLD MEDICAL,INC. | $23 | Food and Beverage | In-kind items and services | Kahook Dual Blade Device, Ophthalmology | 2022 | |
| 2022-04-26 | Alcon Vision LLC | $19 | Food and Beverage | In-kind items and services | AcrySof IQ PanOptix UV IOL Device, Ophthalmology | 2022 | |
| 2022-03-23 | Novartis Pharmaceuticals Corporation | $907 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2021-12-06 | Aerie Pharmaceuticals, Inc. | $15 | Food and Beverage | In-kind items and services | rhopressa Drug, Glaucoma | 2021 | |
| 2021-11-13 | EyePoint Pharmaceuticals US, Inc. | $82 | Food and Beverage | In-kind items and services | DEXYCU Drug, Postoperative Inflammation | 2021 | |
| 2021-01-28 | EyePoint Pharmaceuticals US, Inc. | $18,720 | Consulting Fee | Cash or cash equivalent | DEXYCU Drug, Postoperative Inflammation | 2021 | |
| 2020-12-29 | Bausch Health US, LLC | $1,500 | Consulting Fee | Cash or cash equivalent | CVISC50 Device, OPHTHALMOLOGY | 2020 | |
| 2020-11-20 | Bausch Health US, LLC | $7 | Consulting Fee | Cash or cash equivalent | CVISC50 Device, OPHTHALMOLOGY | 2020 | |
| 2020-03-13 | EyePoint Pharmaceuticals US, Inc. | $6,980 | Consulting Fee | Cash or cash equivalent | DEXYCU Drug, Postoperative Inflammation | 2020 | |
| 2019-11-26 | Osmotica Pharmaceutical Corp. | $5,700 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-10-25 | Osmotica Pharmaceutical Corp. | $23 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-24 | Osmotica Pharmaceutical Corp. | $136 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-13 | Osmotica Pharmaceutical Corp. | $23 | Food and Beverage | Cash or cash equivalent | 2019 | ||
| 2019-10-12 | EyePoint Pharmaceuticals US, Inc. | $71 | Food and Beverage | In-kind items and services | YUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis | 2019 | |
| 2019-10-11 | Novartis Pharmaceuticals Corporation | $50 | Food and Beverage | In-kind items and services | XIIDRA Drug, OPHTHALMOLOGY | 2019 | |
| 2019-06-26 | EyePoint Pharmaceuticals US, Inc. | $1,200 | Consulting Fee | Cash or cash equivalent | DEXYCU Drug, Postoperative Inflammation | 2019 | |
| 2019-05-04 | Allergan, Inc. | $81 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-04-06 | Novartis Pharmaceuticals Corporation | $127 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-04-06 | Novartis Pharmaceuticals Corporation | $99 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-04-06 | Novartis Pharmaceuticals Corporation | $28 | Travel and Lodging | Cash or cash equivalent | 2019 | ||
| 2019-04-06 | Novartis Pharmaceuticals Corporation | $24 | Travel and Lodging | In-kind items and services | 2019 | ||
| 2019-04-05 | Novartis Pharmaceuticals Corporation | $120 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-03-29 | SUN PHARMACEUTICAL INDUSTRIES INC. | $17 | Food and Beverage | Cash or cash equivalent | XELPROS Drug, Ophthalmology | 2019 | |
| 2019-02-19 | Bausch Health US, LLC | $15,150 | Research payment | Cash or cash equivalent | AZOPT Drug, OPHTHALMOLOGY | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOL | 2019 |
| 2019-01-14 | Bausch Health US, LLC | $11,160 | Research payment | Cash or cash equivalent | AZOPT Drug, OPHTHALMOLOGY | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVELENCE STUDY OF THE GENERIC BRINZOL | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-10-15 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $12,615 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-10-15 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $9,767 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-08-14 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $16,406 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-08-14 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $5,831 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-06-13 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $13,297 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-04-28 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $7,816 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-04-28 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $9,945 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-03-19 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $20,580 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-02-10 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $29,826 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2025-01-17 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $20,742 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2025 |
| 2024-11-22 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $13,532 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2024 |
| 2024-11-06 | Glaukos Corporation | Michael S. Korenfeld dba Vision Research Institute, LLC | $1,500 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-10-10 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $2,788 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2024 |
| 2024-07-19 | Oyster Point Pharma, Inc. | Vision Research Institute, LLC | $3,000 | A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% | 2024 |
| 2024-07-03 | Glaukos Corporation | Michael S. Korenfeld dba Vision Research Institute, LLC | $500 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-06-05 | Glaukos Corporation | Michael S. Korenfeld dba Vision Research Institute, LLC | $3,463 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-05-08 | Glaukos Corporation | Michael S. Korenfeld dba Vision Research Institute, LLC | $2,318 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-04-03 | Glaukos Corporation | Amazon.com, Inc. | $13 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-04-03 | Glaukos Corporation | Amazon.com, Inc. | $1 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-04-03 | Glaukos Corporation | Michael S. Korenfeld dba Vision Research Institute, LLC | $940 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-03-06 | Glaukos Corporation | Michael S. Korenfeld dba Vision Research Institute, LLC | $3,857 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2024-01-24 | Glaukos Corporation | OCPC | $58 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2024 |
| 2023-10-20 | Glaukos Corporation | Schlenker Ventures LLC | $27 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2023 |
| 2023-03-21 | Glaukos Corporation | Schlenker Ventures LLC | $6 | Multicenter, Randomized, Double-Masked, Active-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Effica | 2023 |
| 2022-01-15 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE EYE CARE LIMITED | $174,116 | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED, MULTI-CENTER, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, AND EFFICACY O | 2022 |
| 2021-12-15 | Bausch Health US, LLC | Vision Research Institute, LLC | $10,420 | A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohe | 2021 |
| 2021-08-04 | Bausch Health US, LLC | Vision Research Institute, LLC | $38,160 | A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohe | 2021 |
| 2021-06-15 | Bausch Health US, LLC | Vision Research Institute, LLC | $28,620 | A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohe | 2021 |
| 2021-06-02 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE EYE CARE LIMITED | $24,882 | A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED, MULTI-CENTER, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, AND EFFICACY O | 2021 |
| 2021-01-21 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE EYE CARE LIMITED | $108,457 | A RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECF843 VS VEHICLE IN SUBJECTS WITH | 2021 |
| 2020-11-09 | Bausch Health US, LLC | Vision Research Institute, LLC | $2,500 | A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohe | 2020 |
| 2020-08-24 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE EYE CARE LIMITED | $10,813 | A RANDOMIZED, DOUBLE-MASKED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECF843 VS VEHICLE IN SUBJECTS WITH | 2020 |
| 2020-08-20 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $5,840 | A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy a | 2020 |
| 2020-06-24 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $4,976 | A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV- | 2020 |
| 2020-05-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $5,574 | A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy a | 2020 |
| 2020-04-21 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $3,528 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2020 |
| 2020-03-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $750 | A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy a | 2020 |
| 2020-03-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $500 | A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy a | 2020 |
| 2020-02-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $1,509 | A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy a | 2020 |
| 2020-02-13 | Novartis Pharmaceuticals Corporation | MICHAEL S KORENFEILD VISION RESEARCH INTITUTE LLC | $26,847 | PHASE II STUDY UNR844 1.5% IN SUBJECTS WITH PRESBYOPIA | 2020 |
| 2020-02-06 | SUN PHARMACEUTICAL INDUSTRIES INC. | VISION RESEARCH INSTITUTE | $6,183 | A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy a | 2020 |
| 2020-01-23 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $600 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2020 |
| 2019-10-17 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $1,800 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-09-18 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $1,050 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-09-04 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $450 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-07-17 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $900 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-06-12 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $1,000 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-05-07 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $4,536 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-04-29 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $13,608 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-04-10 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $4,536 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-03-27 | Novartis Pharmaceuticals Corporation | COMPREHENSIVE EYE CARE | $111,903 | PHASE II STUDY UNR844 1.5% IN SUBJECTS WITH PRESBYOPIA | 2019 |
| 2019-03-07 | Osmotica Pharmaceutical Corp. | COMPREHENSIVE EYE CARE LTD | $600 | RVL-202 | 2019 |
| 2019-03-07 | Osmotica Pharmaceutical Corp. | COMPREHENSIVE EYE CARE LTD | $6,162 | RVL-202 | 2019 |
| 2019-03-07 | Osmotica Pharmaceutical Corp. | COMPREHENSIVE EYE CARE | $631 | RVL-203 | 2019 |
| 2019-03-05 | Kala Pharmaceuticals, Inc. | VISION RESEARCH INSTITUTE LLC | $1,000 | Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease | 2019 |
| 2019-02-06 | Osmotica Pharmaceutical Corp. | COMPREHENSIVE EYE CARE | $2,837 | RVL-203 | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Washington, MO, county Franklin County, MO, state Missouri; placed by its city name.
| Measure | Place (city or town) Washington, MO | County Franklin County, MO | State Missouri |
|---|---|---|---|
| Population B01003 | 15,130 | 105,950 | 6,191,814 |
| Population, 2020 census P1 | 14,500 | 104,682 | 6,154,913 |
| Median age B01002 | 43.1 | 41.8 | 39.0 |
| Under 18 B01001 | 20.9% | 22.4% | 22.3% |
| 65 and over B01001 | 20.1% | 19.2% | 17.9% |
| Households B11001 | 6,702 | 43,036 | 2,508,227 |
| Foreign born B05002 | 0.9% | 1.4% | 4.5% |
| Median household income B19013 | $79,173 | $73,165 | $70,702 |
| Median family income B19113 | $105,811 | $90,136 | $91,360 |
| Per capita income B19301 | $42,762 | $37,792 | $39,695 |
| Poverty rate B17001 | 7.9% | 8.2% | 12.6% |
| Unemployment rate B23025 | 3.8% | 4.3% | 4.0% |
| Civilian labor force B23025 | 8,054 | 52,951 | 3,120,639 |
| Mean commute (minutes) B08013 | 21.1 | 28.3 | 23.5 |
| Bachelor's degree or higher B15003 | 32.3% | 23.7% | 32.4% |
| Housing units B25001 | 6,889 | 46,312 | 2,825,287 |
| Owner-occupied B25003 | 74.0% | 76.5% | 68.1% |
| Renters B25003 | 26.0% | 23.5% | 31.9% |
| Median home value B25077 | $231,800 | $227,600 | $230,300 |
| Median gross rent B25064 | $827 | $893 | $1,033 |
| White, not Hispanic B03002 | 91.7% | 88.7% | 76.3% |
| Black B03002 | 0.3% | 0.9% | 10.9% |
| Hispanic or Latino B03002 | 2.1% | 2.3% | 5.2% |
| Asian B03002 | 0.2% | 0.4% | 2.1% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Washington, MO.
Comments